

Figure S1: Antibody based suspension bead assay concepts. The antibody raised towards intended protein target is covalently coupled to colour-coded micrometre-sized beads. (A) In the single binder assay, all proteins within the plasma sample are labelled with biotin before incubation with beads. Biotin-labelled proteins bound to the capture antibody are detected by fluorescent-labelled-streptavidin. The suspension is analysed by a cytometry-based instrument (Luminex), where the colour of the antibody-coupled bead provides the antibody ID, and the mean fluorescence intensity provides a relative measure of the bound target protein corresponding to plasma levels. (B) In the dual binder assay captured proteins are unlabelled, and detection of target protein bound to the capture antibody is through a secondary target-specific biotin-labelled detection antibody, followed by fluorescent-labelled-streptavidin addition and analysis on a Luminex instrument. As detection in the single binder assay is based on detection of biotin bound directly to target proteins, the signal can reflect either (C) the intended on-target binding, (D) co-target binding where the target protein is

 $complexed \ with \ non-target \ protein \ or \ \textbf{(E)} \ off-target \ binding, \ i.e., \ binding \ of \ a \ non-target \ protein.$

(**F**) An amino-acid substitution in the epitope of the target protein can lead to iso-form specific binding.




Figure S2: Recombinant CFHR5 does not potentiate platelet activation of washed platelets. Platelet activation was measured by surface expression of (A) P-selectin, (B) activated GP IIb/IIIa or (C) CD63, following treatment of washed platelets with different concentrations of (i) adenosine diphosphate (ADP) (ii) convulxin or (iii) TRAP6, following preincubation (10 minutes) with 6 μg/ml recombinant CFHR5, or PBS control. Each experiment is represented by an individual point and paired experiments connected by a dotted line.

Data file Table S1:

- Tab_1: Antibody reagents and target protein IDs from analysis of *VEBIOS ER* discovery study
- Tab_2: List of proteins identified in plasma by IC-MS using antibody HPA059937
- Tab 3: Association between CFHR5 plasma levels and clinical variables in VEBIOS ER
- Tab 4: CFHR5 mRNA co-expression profile in human liver
- Tab_5: STRING protein-protein interaction analysis between CFHR5-related transcripts
- Tab 6: Relative risk of VTE associated with CFHR5 by thrombosis type and sex
- Tab 7: Genetic risk association of VTE
- Tab 8: Thrombin generation potential analysis in MARTHA and RETROVE

Data file Table S2:

- Tab_1: Clinical characteristics: Extended VEBIOS Coagulation sample set
- Tab 2: Clinical characteristics: DFW-VTE sample set
- Tab 3: Clinical characteristics: FARIVE sample set
- Tab_4: Clinical characteristics: RETROVE sample set
- Tab_5: Clinical characteristics: MARTHA sample sets
- Tab 6: Clinical characteristics: COMMUNITY study